General Information of Drug (ID: DMKICA3)

Drug Name
BIO-1211 Drug Info
Synonyms
BIO-1211; BIO 1211; 187735-94-0; UNII-61G4E2353I; CHEMBL88478; 61G4E2353I; BIO1211; GTPL6589; SCHEMBL1223367; MolPort-023-276-985; ZINC3930111; BDBM50074661; AKOS024457866; L-Proline, N-(2-(4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl-; L-Proline, N-((4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl-
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 2 [1]
Cross-matching ID
PubChem CID
9961766
CAS Number
CAS 187735-94-0
TTD Drug ID
DMKICA3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Integrin alpha-4 (ITGA4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vedolizmab DMV3YMX Crohn disease DD70 Approved [3]
Antegren DMNC64R Multiple sclerosis 8A40 Approved [4]
Natalizumab DMAK85L Crohn disease DD70 Approved [5]
PB006 DMVHGLA Crohn disease DD70 Phase 3 [6]
GSK683699 DMTW79H Inflammatory bowel disease DD72 Phase 2 [7]
AMG-181 DMODJTX Crohn disease DD70 Phase 2 [8]
Senktide DMOH8LD Epilepsy 8A60-8A68 Phase 2 [9]
PTG-100 DMQNRGE Ulcerative colitis DD71 Phase 1 [8]
ELND-002 DMM9S51 Autoimmune diabetes 5A10 Phase 1 [10]
ELND-004 DMLQYVD Autoimmune diabetes 5A10 Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-4 (ITGA4) TT4BT06 ITA4_HUMAN Antagonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6589).
2 A small-molecule, tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):603-11.
3 Clinical pipeline report, company report or official report of Takeda (2009).
4 Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol. 1998 Aug;2(4):453-7.
5 Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front Immunol. 2020 Sep 24;11:549842.
6 Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial. JAMA Neurol. 2023 Mar 1;80(3):298-307.
7 Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8.